Influence of a half-marathon run on NT-proBNP and troponin T.

BACKGROUND A caveat to strenuous and medium term physical exercise is the potential cardiovascular damage it may cause. In particular, there is still controversy regarding the behaviour of biochemical markers of heart damage and dysfunction following medium term endurance training. METHODS Troponin T (TnT) and the N-terminal proB-type natriuretic peptide (NT-proBNP) were assessed before a 21-km half-marathon, at the end, and 3, 6, 24 h thereafter on 17 trained, middle-aged males. Results were corrected for plasma volume changes. RESULTS All athletes finished the half-marathon run successfully and without any symptoms. Most of them were able to fulfill their personal expectations. The % PVC increased significantly immediately after the run, returned to values not significantly different from the baseline at 3 and 6 h, and showed a significant decrease of 4.4% on the following day. None of the cases showed an increase in the concentration of TnT the > 0.03 ng/ml threshold. Although the level of NT-proBNP increased significantly at the end of the run and remained statistically higher than the pre-half marathon value for the following 24 h, no athlete displayed values exceeding the cut-off concentration of 125 pg/mL. At any time point the delta increments of NT-proBNP from the pre-run values did not significantly correlate with the corresponding % PVC. CONCLUSIONS Taken together, our results in healthy, middle-aged, trained individuals are consistent with the hypothesis that medium term aerobic exercise significantly influences NT-proBNP values for up to 24 h though no biochemical signs of myocardial necrosis can be detected.

[1]  A. Jaffe,et al.  Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and N-terminal pro-brain natriuretic peptide. , 2007, Clinical chemistry.

[2]  C. Schindler,et al.  Medical and economic long-term effects of B-type natriuretic peptide testing in patients with acute dyspnea. , 2007, Clinical chemistry.

[3]  Claudio Passino,et al.  Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. , 2007, Clinical chemistry.

[4]  T. Neilan,et al.  Elevation of myeloperoxidase in conjunction with cardiac-specific markers after marathon running. , 2006, American journal of clinical pathology.

[5]  J. Marshall,et al.  Myocardial Injury and Ventricular Dysfunction Related to Training Levels Among Nonelite Participants in the Boston Marathon , 2006, Circulation.

[6]  J. Mair,et al.  Utility of N-terminal pro-B-type natriuretic peptide to differentiate cardiac diseases from noncardiac diseases in young pediatric patients. , 2006, Clinical chemistry.

[7]  T. Meyer,et al.  Reproducibility and clinical significance of exercise-induced increases in cardiac troponins and N-terminal pro brain natriuretic peptide in endurance athletes , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[8]  G. Lippi,et al.  Influence of physical exercise and relationship with biochemical variables of NT-pro-brain natriuretic peptide and ischemia modified albumin. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[9]  M. Panteghini,et al.  10% CV concentration for the fourth generation Roche cardiac troponin T assay derived from Internal Quality Control data , 2006, Clinical chemistry and laboratory medicine.

[10]  C. Herzog,et al.  Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. , 2004, Clinical chemistry.

[11]  David A Morrow,et al.  BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. , 2004, Congestive heart failure.

[12]  W. Herrmann,et al.  No difference in N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations between endurance athletes with athlete’s heart and healthy untrained controls , 2004, Heart.

[13]  P O Collinson,et al.  Analytical performance of the N terminal pro B type natriuretic peptide (NT‐proBNP) assay on the Elecsys™ 1010 and 2010 analysers , 2004, European journal of heart failure.

[14]  Wen-Sheng Huang,et al.  Circulating brain natriuretic peptide values in healthy men before and after exercise. , 2002, Metabolism: clinical and experimental.

[15]  D. Costill,et al.  Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration. , 1974, Journal of applied physiology.